In addition, the combination of interleukin-2 (IL-2) therapy induces stem cell like depleted T cells to differentiate into high affinity IL-2 receptor (CD25+) effector T cells by activating STAT5 signal, thereby reshaping the anti-tumor immune response and further enhancing the blocking effect of PD-1 [52]. The gene discussed is IL2; the disease is neoplasm.